159 related articles for article (PubMed ID: 25293620)
1. Irreversible electroporation: a novel therapy for stage III pancreatic cancer.
Weiss MJ; Wolfgang CL
Adv Surg; 2014; 48():253-8. PubMed ID: 25293620
[No Abstract] [Full Text] [Related]
2. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma].
Kawaida H; Fujii H
Nihon Rinsho; 2015 Mar; 73 Suppl 3():181-5. PubMed ID: 25857011
[No Abstract] [Full Text] [Related]
3. Multidisciplinary management of locally advanced pancreatic ductal adenocarcinoma.
Alemi F; Alseidi A; Scott Helton W; Rocha FG
Curr Probl Surg; 2015 Sep; 52(9):362-98. PubMed ID: 26363649
[No Abstract] [Full Text] [Related]
4. [Pancreatic cancer- a curable disease].
Limani P; Samaras P; Lesurtel M; Graf R; DeOliveira ML; Petrowsky H; Clavien PA
Praxis (Bern 1994); 2015 Apr; 104(9):453-60. PubMed ID: 25900693
[TBL] [Abstract][Full Text] [Related]
5. What is the major prognostic factor in tumor-node-metastasis staging of pancreatic adenocarcinoma?
Santi I; Brandt A; Hemminki K
Ann Surg Oncol; 2011 Jan; 18(1):300-1. PubMed ID: 20589435
[No Abstract] [Full Text] [Related]
6. Metastatic Pancreatic Cancer.
Hogendorf P; Durczyński A; Strzelczyk J
J Invest Surg; 2018 Apr; 31(2):151-152. PubMed ID: 28267398
[No Abstract] [Full Text] [Related]
7. Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment.
Lin M; Liang S; Wang X; Liang Y; Zhang M; Chen J; Niu L; Xu K
J Cancer Res Clin Oncol; 2017 Dec; 143(12):2607-2618. PubMed ID: 28871458
[TBL] [Abstract][Full Text] [Related]
8. Stage III pancreatic cancer and the role of irreversible electroporation.
Al Efishat M; Wolfgang CL; Weiss MJ
BMJ; 2015 Mar; 350():h521. PubMed ID: 25787829
[TBL] [Abstract][Full Text] [Related]
9. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
Hong Y; Rice J; Sharma D; Martin RCG
Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant therapy in pancreatic cancer.
Jones OP; Melling JD; Ghaneh P
World J Gastroenterol; 2014 Oct; 20(40):14733-46. PubMed ID: 25356036
[TBL] [Abstract][Full Text] [Related]
11. Irreversible electroporation for Stage III locally advanced pancreatic cancer: Single-center experience.
Spiliotis J; Kopanakis N; Terras A; Efstathiou E
J BUON; 2018; 23(4):1203-1204. PubMed ID: 30358236
[No Abstract] [Full Text] [Related]
12. A single institution experience of the treatment of pancreatic ductal carcinoma: The demand and the role of radiation therapy.
Kubo K; Wadasaki K; Komichi D; Sasaki T; Yamada H; Matsugu Y; Itamoto T; Doi M; Shinozaki K
PLoS One; 2019; 14(12):e0227305. PubMed ID: 31887205
[TBL] [Abstract][Full Text] [Related]
13. The challenges of improving survival following pancreatoduodenectomy for pancreatic ductal adenocarcinoma.
Shukla PJ
Ann Surg; 2011 Aug; 254(2):385-6; author reply 386. PubMed ID: 21677560
[No Abstract] [Full Text] [Related]
14. Effects of perioperative red blood cell transfusion on disease recurrence and survival after pancreaticoduodenectomy for ductal adenocarcinoma.
Kneuertz PJ; Patel SH; Chu CK; Maithel SK; Sarmiento JM; Delman KA; Staley CA; Kooby DA
Ann Surg Oncol; 2011 May; 18(5):1327-34. PubMed ID: 21369744
[TBL] [Abstract][Full Text] [Related]
15. Causes of Death and Conditional Survival Estimates of Medium- and Long-term Survivors of Pancreatic Adenocarcinoma.
Swords DS; Mulvihill SJ; Firpo MA; Scaife CL
JAMA Oncol; 2018 Aug; 4(8):1129-1130. PubMed ID: 30003235
[TBL] [Abstract][Full Text] [Related]
16. Invasive intraductal papillary-mucinous neoplasm of the pancreas: comparison with pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hayashidani Y; Hashimoto Y; Nakashima A; Sueda T
J Surg Oncol; 2009 Jul; 100(1):13-8. PubMed ID: 19384908
[TBL] [Abstract][Full Text] [Related]
17. Treatment of 200 locally advanced (stage III) pancreatic adenocarcinoma patients with irreversible electroporation: safety and efficacy.
Martin RC; Kwon D; Chalikonda S; Sellers M; Kotz E; Scoggins C; McMasters KM; Watkins K
Ann Surg; 2015 Sep; 262(3):486-94; discussion 492-4. PubMed ID: 26258317
[TBL] [Abstract][Full Text] [Related]
18. Follow-up after curative surgery for pancreatic ductal adenocarcinoma: asymptomatic recurrence is associated with improved survival.
Nordby T; Hugenschmidt H; Fagerland MW; Ikdahl T; Buanes T; Labori KJ
Eur J Surg Oncol; 2013 Jun; 39(6):559-66. PubMed ID: 23498362
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic ductal carcinoma: from the bench to the bedside.
Pezzilli R
JOP; 2006 Sep; 7(5):508-10. PubMed ID: 16998251
[No Abstract] [Full Text] [Related]
20. Intraductal papillary mucinous neoplasms (IPMNs): is it time to (sometimes) spare the knife?
Bassi C; Crippa S; Salvia R
Gut; 2008 Mar; 57(3):287-9. PubMed ID: 18268051
[No Abstract] [Full Text] [Related]
[Next] [New Search]
